Overview Request Sample Pages Request Customization Download PDF
You are viewing: China Biochips Market analysis
Part of: Biochips Market (Global)

The China Biochips Market was valued at $1182 Million in 2025 and projected to reach to $2022.9 Million by 2030, representing a compound annual growth rate of 11.3%. China's biochips market is positioned for exceptional growth through 2030, driven by government support for biotechnology advancement and increasing healthcare expenditure.

China Biochips Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Biochips Market Trends and Insights

  • This accelerated growth in China significantly outpaces the global biochips market CAGR of 8.8%, reflecting the country's substantial investments in healthcare innovation and biotechnology infrastructure.
  • China's strategic focus on precision medicine, diagnostic advancement, and domestic semiconductor capabilities is driving rapid adoption of biochip technologies across clinical and research applications. The biochips market in China is propelled by increasing healthcare expenditure, rising prevalence of chronic diseases, and government initiatives supporting life sciences development.
  • China's position as a global manufacturing hub and its growing research capabilities position the country as a critical market for biochip innovation and commercialization.
  • Between 2025 and 2030, China is expected to capture significant market share within the Asia Pacific region, driven by expanding pharmaceutical R&D, personalized medicine demand, and integration of artificial intelligence with biochip diagnostics..

Key Market Statistics

  • CAGR (2025-2030) 11.3% CAGR
  • Market Size, 2025 ~USD 1182 Million
  • Forecast, 2030 ~USD 2022.9 Million
  • Country China

China Biochips Market Overview

Rapid Market Expansion :

China's biochips market is growing at 11.3% CAGR, significantly outpacing the global rate of 8.8%, driven by government initiatives in biotechnology and healthcare modernization.

Substantial Valuation Growth :

The market is projected to expand from USD 1,182.0 million in 2025 to USD 2,022.9 million by 2030, representing an 71% increase over five years.

Government Investment Focus :

China's strategic investments in healthcare innovation and biotechnology infrastructure are accelerating biochip adoption across diagnostic, therapeutic, and research applications.

Emerging Healthcare Demand :

Rising prevalence of chronic diseases, aging population, and increased healthcare spending are creating substantial demand for advanced biochip diagnostic and monitoring solutions.

China Biochips Market Dynamics

  • The country's focus on precision medicine and personalized diagnostics is accelerating biochip adoption across hospitals, research institutions, and diagnostic laboratories.
  • Domestic manufacturers are expanding production capabilities while international players establish regional partnerships to capture market share. The competitive landscape is intensifying as Chinese biotech companies develop indigenous biochip technologies.
  • Investment in R&D infrastructure, coupled with favorable regulatory frameworks, will continue to attract both domestic and foreign capital.
  • By 2030, China is expected to become a significant global hub for biochip innovation and manufacturing, supported by its large patient population and healthcare modernization initiatives..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • China's biochips market will grow from USD 1,182.0M (2025) to USD 2,022.9M (2030) at an 11.3% CAGR, outpacing global growth.
      • China's government support for biotechnology and precision medicine initiatives is accelerating biochip adoption and innovation.
      • China's manufacturing expertise and semiconductor capabilities position the country as a key hub for biochip production and development.
      • Rising chronic disease prevalence and healthcare spending in China are driving demand for advanced diagnostic biochip solutions.

      Biochips Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment MICROFLUIDICS (Fabrication Technology)
      Forecast Period 2025–2030
      Growth Rate CAGR of 8.8% from 2025 to 2030
      Largest Segment MICROARRAYS (Fabrication Technology)
      Market Size Base Year (Billions) ~USD 14.01 (2025)
      Revenue Forecast (Billions) ~USD 21.36 (2030)
      Segments Covered Products & Services, Type, Application, Fabrication Technology, End User, Product & Service

      China Biochips Market Report Segmentation

      6 segment dimensions are covered across the global market.

      By Products & Services

      • Consumables
      • Instruments
      • Software & Services

      By Type

      • Cell Arrays
      • Dna Chips
      • Lab-On-A-Chip
      • Protein Chips
      • Tissue Arrays

      By Application

      • Agricultural Biotechnology
      • Cancer Diagnosis & Treatment
      • Clinical Diagnostic
      • Diagnostics
      • Drug Discovery
      • Expression Profiling
      • Gene Expression
      • Genomics
      • High-Throughput Screening
      • Ivd & Poc
      • Other Dna Chip Applications
      • Other Loac Applications
      • Other Protein Chip Applications
      • Proteomics
      • Snp Genotyping

      By Fabrication Technology

      • Microarrays
      • Microfluidics

      By End User

      • Academic & Research Institutes
      • Biotechnology & Pharmaceutical Companies
      • Contract Research Organizations
      • Hospitals & Diagnostic Centers
      • Other End Users

      By Product & Service

      • Consumables
      • Instruments
      • Software & Services

      CHINA: BIOCHIPS MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      ACADEMIC & RESEARCH INSTITUTES100.2110.9122.7136150.6166.9185.3205.810.9
      BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES521.2582650.3727.1812.8909.51018.7114211.9
      CONTRACT RESEARCH ORGANIZATIONS61.569.378.18899.3112126.514312.9
      HOSPITALS & DIAGNOSTIC CENTERS211.9232.2254.5279.1306.1336.1369.3406.29.8
      OTHER END USERS62.869.276.484.393.1102.8113.7125.910.5
      TOTAL957.71063.611821314.51461.81627.31813.62022.911.3

      Target Audience

      • Biochip Manufacturers & Developers : Need market sizing and growth forecasts to plan production capacity, R&D investments, and commercialization timelines for China's rapidly expanding biochip market.
      • Healthcare & Diagnostic Companies : Require detailed market intelligence to identify biochip integration opportunities, assess competitive threats, and develop China-specific product and distribution strategies.
      • Investment & Private Equity Firms : Seek validated market data and growth projections to evaluate investment opportunities, assess portfolio company potential, and identify acquisition targets in China's biotech sector.
      • Government & Policy Makers : Need market analysis to inform healthcare policy, biotechnology funding decisions, and regulatory frameworks supporting China's biochip innovation and adoption goals.
      • Research Institutions & Consultants : Require comprehensive market data and forecasts to support strategic consulting engagements, academic research, and competitive benchmarking for China's biochip landscape.

      Key Companies in the China Biochips Market

      CompanyHQOwnershipStrongest segments
      ATS AUTOMATION TOOLING SYSTEMS INCCanadaPublic CompanyCustom automated manufacturing and assembly systems,Pre- and post-automation services,Software and digital factory solutions,
      DECODE GENETICSIcelandPrivate CompanyInternal discovery and target validation for Amgen,External research collaborations and licensing,Population genomics and healthcare-linked projects,
      JABILUnited StatesPublic CompanyRegulated Industries (Healthcare, Automotive, Industrial, Packaging),Intelligent Infrastructure (5G, Cloud, Networking, Storage, Digital Building),Connected Living and Digital Commerce (Mobility, Connected Devices, Retail, Digital Commerce Ecosystem),
      AT&SCanadaPublic CompanyTurnkey automation systems (design, build, commissioning),Lifecycle services (pre- and post-automation, maintenance, retrofits),Contract manufacturing and integration,
      X-FABBelgiumPublic CompanyAutomotive analog & mixed-signal (incl. high-voltage, BCD, safety ICs),Power semiconductors (SiC, GaN, high-voltage discretes),MEMS & sensor platforms (pressure, inertial, image, gas/flow, photodiodes),
      GE HEALTHCAREUnited StatesPublic CompanyImaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS),
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response (TB and transplant) assays,Oncology, sexual and reproductive health assays,
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics systems, reagents, and quality controls,Life Science instruments and consumables for research and biopharma,Informatics and software solutions,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      STANDARD BIOTOOLSUnited StatesPublic CompanyProteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics platforms and consumables (Biomark X9 and qPCR systems),Services, software, and other,
      10X GENOMICSUnited StatesPublic CompanyChromium instruments,Chromium consumables & kits (incl. QuantumScale),Visium spatial platform (instruments, slides, reagents),
      CEPHEIDUnited StatesPrivate CompanyGeneXpert instruments,Xpert test cartridges (infectious disease & HAIs),Xpert test cartridges (virology, oncology, genetics),
      BIOMéRIEUXFrancePublic CompanyClinical microbiology (VITEK, BACT/ALERT, CHROMID, culture media, ETEST, API),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, EPISEQ),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA),
      REVVITYUnited StatesPublic CompanyDiagnostics & Immunodiagnostics (prenatal, newborn, infectious, autoimmune, specialty),Life Science Reagents & Assay Platforms,Genomic & NGS Workflow Solutions,
      DIASORIN S.P.A.ItalyPublic CompanyImmunodiagnostics (LIAISON XL / XS reagents and systems),Molecular diagnostics (Simplexa, LIAISON PLEX assays),xMAP technology and other specialty IVD solutions,

      ATS AUTOMATION TOOLING SYSTEMS INC

      ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 that employs 7,000 people. The company specializes in automation and tooling systems for industrial applications.

      DECODE GENETICS

      Decode Genetics is a private Icelandic company founded in 1996 with 331 employees. The company focuses on genetic research and analysis.

      JABIL

      Jabil is a large American public company founded in 1966 with 135,000 employees. The company provides electronics manufacturing services and solutions.

      AT&S

      AT&S is a Canadian public company founded in 1978 with 7,000 employees. The company specializes in automation and tooling systems.

      X-FAB

      X-FAB is a Belgian public semiconductor company founded in 1992 with 4,300 employees. The company manufactures specialty semiconductor products.

      GE HEALTHCARE

      GE Healthcare is an American public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a large American public company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, and services for research and diagnostics.

      ILLUMINA, INC.

      Illumina, Inc. is an American public company founded in 1998 with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is an American public company founded in 1999 with 18,000 employees. The company provides analytical instruments and software for life sciences and diagnostics.

      QIAGEN

      Qiagen is a Dutch public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation products.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is an American public company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research and clinical diagnostics products.

      ABBOTT

      Abbott is a large American public company founded in 1888 with 115,000 employees. The company develops and manufactures pharmaceuticals, diagnostics, and medical devices.

      STANDARD BIOTOOLS

      Standard Biotools is an American public company founded in 1999 with 387 employees. The company develops microfluidic and single-cell analysis solutions.

      10X GENOMICS

      10X Genomics is an American public company founded in 2012 with 1,178 employees. The company develops single-cell and spatial genomics solutions.

      CEPHEID

      Cepheid is an American private company founded in 1996 with 1,700 employees. The company manufactures molecular diagnostics and point-of-care testing systems.

      BIOMéRIEUX

      bioMérieux is a French public company founded in 1963 with 14,894 employees. The company develops and manufactures in vitro diagnostics and microbiology testing systems.

      REVVITY

      Revvity is an American public company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.

      DIASORIN S.P.A.

      DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees. The company develops and manufactures in vitro diagnostic products.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Obtain precise valuation data for China's biochips market with verified CAGR of 11.3%, enabling accurate financial forecasting and investment decision-making for the region.
      • Competitive Intelligence : Understand China's market dynamics, identify key players, and assess competitive positioning to develop effective market entry or expansion strategies in this high-growth segment.
      • Investment Opportunity Assessment : Evaluate the 71% market growth potential from 2025-2030 to identify optimal investment windows, partnership opportunities, and acquisition targets in China's biochip ecosystem.
      • Regulatory & Policy Insights : Gain clarity on China's healthcare policies, government incentives, and regulatory frameworks driving biochip adoption and innovation across diagnostic and therapeutic applications.
      • Strategic Planning & Forecasting : Leverage detailed market projections and trend analysis to inform product development, market positioning, and resource allocation strategies specific to the Chinese market.

      Frequently asked questions

      What is the projected size of China's biochips market by 2030?

      China's biochips market is projected to reach USD 2,022.9 million by 2030, growing from USD 1,182.0 million in 2025.

      What is the CAGR for China's biochips market from 2025 to 2030?

      China's biochips market is expected to grow at a compound annual growth rate of 11.3% between 2025 and 2030.

      How does China's biochips market growth compare to global trends?

      China's biochips market CAGR of 11.3% exceeds the global market CAGR of 8.8%, indicating faster growth in China than worldwide.

      What factors are driving growth in China's biochips market?

      Key drivers include government biotechnology initiatives, rising healthcare expenditure, increasing chronic disease prevalence, and China's semiconductor manufacturing capabilities.

      What role does China play in the Asia Pacific biochips market?

      China is a dominant market within Asia Pacific, leveraging its manufacturing expertise, research capabilities, and healthcare investments to capture significant regional market share.

      RESEARCH METHODOLOGY

      This research study extensively utilized both primary and secondary sources. It involved analyzing various factors influencing the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and strategies employed by key players.

      Secondary Research

      This research study utilized a variety of comprehensive secondary sources, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the biochips market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments pertaining to both market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.

      Primary Research

      In the primary research process, we interviewed a range of sources from both the supply and demand sides to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the biochips market. Primary sources from the demand side include researchers in biotechnology and pharmaceutical companies, healthcare professionals from hospitals and diagnostic centers, academic & research institutes and contract research organizations.

      A breakdown of the primary respondents is provided below:

      Biochips Market

      Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.

      Note 2: Other designations include sales, marketing, and product managers.

      Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The total size of the biochips market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

      Biochips Market

      Data Triangulation

      After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

      Market Definition

      The biochips market refers to miniaturized analytical platforms integrating biological probes or microfluidic components that allow simultaneous or rapid analysis of DNA, RNA, proteins, metabolites, or tissues. They are fabricated as microarrays, microfluidic cartridges, or tissue arrays and used in diagnostics, genomics, proteomics, drug discovery, and pathology research. These biochips enable high-throughput screening, providing faster, more efficient testing methods, and are critical in applications such as personalized medicine, disease detection, and environmental monitoring. With advances in technology, biochips are becoming increasingly versatile, supporting the development of novel diagnostics and therapeutic solutions across multiple sectors.

      Stakeholders

      • Pharmaceutical Companies
      • Biotechnology Companies
      • Research Institutes
      • Academic Institutes
      • Contract Research Organizations
      • Research and Consulting Companies
      • Biochip Manufacturers and Distributors
      • DNA & Gene Chip Manufacturers and Distributors
      • Protein Microarray Manufacturers and Distributors
      • Lab-on-a-Chip Manufacturers and Distributors
      • Cell & Tissue Array Manufacturers and Distributors

      Report Objectives

      • To define, describe, segment, and forecast the biochips market by products & services, type, fabrication technology, end user, and region
      • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biochips market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the biochips market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
      • To profile the key players in the biochips market and comprehensively analyze their core competencies and market shares
      • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

       

      Get the Full Biochips Market Report

      Full forecast, segment splits, and company analysis for all Biochips Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status